_PRIVATE_LIMITED.webp)
Wens Durgs (India) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.15 M
- Company Age 22 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.45 Cr
- Revenue Growth %
- Profit Growth -103.62%
- Ebitda 69.61%
- Net Worth -1.49%
- Total Assets -1.44%
About Wens Durgs (India)
Wens Durgs (India) Private Limited (WDIPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 July 2002 and has a history of 22 years and seven months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.15 M.
The company currently has active open charges totaling ₹1.45 Cr.
Suheem Nomani and Saleem Nomani serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230MH2002PTC136387
- Company No.
136387
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jul 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Wens Durgs (India)?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suheem Nomani  | Director | 01-Apr-2006 | Current |
| Saleem Nomani | Director | 15-Sep-2021 | Current |
Financial Performance of Wens Durgs (India).
Wens Durgs (India) Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 103.62% decrease in profit. The company's net worth dipped by a decrease of 1.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wens Durgs (India)?
In 2023, Wens Durgs (India) had a promoter holding of 73.33% and a public holding of 26.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Wens Remedies Private LimitedSuheem Nomani and Saleem Nomani are mutual person
- Wens Pharma Private Limited
Suheem Nomani is a mutual person
- Wens Fashion Llp
Saleem Nomani is a mutual person
Charges (Loans)
₹14.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 1.00 Cr
- Union Bank Of India : 0.45 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Mar 2024 | Others | ₹1.00 Cr | Open |
| 17 Apr 2012 | Union Bank Of India | ₹4.50 M | Open |
How Many Employees Work at Wens Durgs (India)?
Unlock and access historical data on people associated with Wens Durgs (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wens Durgs (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wens Durgs (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
